Fig. 2From: Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label studyeGFR annualized slope in males, females, and overall study population (efficacy population). eGFR estimated glomerular filtration rate, SE standard errorBack to article page